Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar Suffix Detractors Hope Private Studies Build Their Case

Executive Summary

Consortium’s biosimilar pharmacovigilance could provide data foundation to pressure FDA that suffixes are not needed in non-proprietary names.


Related Content

Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting
Generic Drug Surveillance Could Be Enhanced By Dispensers Recording NDC, Manufacturer Data
Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi
Biosimilars Surveillance Program Gears Up For Infliximab And Insulin
Sentinel For Biosimilars? Biologics Post-Market Monitoring Is Focus Of New Consortium
Biosimilar User Fees Could Be Raised Significantly In Renewal Talks
FDA Biosimilar Naming Policy Takes Middle-Of-The-Road Approach
Sandoz Tells FDA Unique Biosimilar Names OK… Sometimes


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts